An Innovative Treatment Giving New Hope to Bladder Cancer Patients

In this special 20th-anniversary episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with leading urologic oncologist Dr. Sia Daneshmand to explore a new bladder cancer therapy: Johnson & Johnson's newly FDA-approved INLEXZO™. Dr. Daneshmand—who helped lead its clinical trials—breaks down how this "pretzel-shaped" intravesical delivery system works, why it's showing some of the highest response rates yet for BCG-unresponsive disease and what patients can realistically expect in terms of side effects, treatment schedule, and quality of life. Together, they discuss the future of drug-delivery technology in bladder cancer and why this moment can offer hope to bladder cancer patients.

There are no comments yet.

Please log in to write the first comment.